Key insights
- President Trump's threat of 50% tariffs on goods from countries supplying military weapons to Iran introduces significant geopolitical and trade uncertainty. This could disrupt global supply chains, particularly for nations involved in such trade, and potentially impact specific sectors like metals and pharmaceuticals. While the direct impact on US equity markets may be limited initially, it signals a return to protectionist trade policies that could weigh on investor sentiment and increase volatility, especially if implemented broadly.
The U.S. will impose tariffs of 50% on “any and all” goods imported to the country from any nation “supplying military weapons to Iran,” President Donald Trump said Wednesday.
Trump said in a Truth Social post that any country found to be supplying Iran with weapons would be subject to the levy “immediately,” with no “exclusions or exemptions.”
The president wrote: “A Country supplying Military Weapons to Iran will be immediately tariffed, on any and all goods sold to the United States of America, 50%, effective immediately. There will be no exclusions or exemptions!”
It came as Trump said the U.S. would “work closely” with Iranian authorities, following the ceasefire agreement announced on Tuesday and what Trump called “very productive regime change.”
Trump said in a separate Truth Social post that “there will be no enrichment of uranium” and that many of the 15 points in the U.S. peace proposals have already been agreed.
The U.S. and Iran will discuss tariffs and sanctions relief, Trump added.
The vast bulk of Trump’s “reciprocal” tariffs, imposed last year, were struck down by the Supreme Court in February.
However, the White House has effectively rebuilt its tariff regime with its application of mechanisms within existing trade laws – such as Section 301 probes.
Metals are a key feature of the existing tariff regime, which currently imposes a 50% levy on products made entirely or almost entirely of steel, aluminum, or copper. There is a 25% tariff on derivative products “substantially made” of these metals.
From late July 2026, larger firms will face a 100% tariff on patented pharmaceutical products and ingredients. Smaller pharma companies will face the new tariff rate from late September.